Mastronuzzi A, Carsetti R, De Ioris M, Agrati C, Del Baldo G, Russo C
Heliyon. 2024; 10(14):e34503.
PMID: 39713186
PMC: 11659958.
DOI: 10.1016/j.heliyon.2024.e34503.
Dou D, Zhang F, Deng X, Ma Y, Wang S, Ji X
Heliyon. 2023; 9(9):e19609.
PMID: 37810049
PMC: 10558877.
DOI: 10.1016/j.heliyon.2023.e19609.
OBrien S, Cole L, Albanese B, Mahon A, Knight V, Williams N
Emerg Infect Dis. 2023; 29(5):929-936.
PMID: 36972709
PMC: 10124638.
DOI: 10.3201/eid2905.221541.
Bronsky J, Copova I, Durilova M, Kazeka D, Kubat M, Lerchova T
J Pediatr Gastroenterol Nutr. 2023; 76(2):e36-e44.
PMID: 36705698
PMC: 9847686.
DOI: 10.1097/MPG.0000000000003661.
Peshevska-Sekulovska M, Bakalova P, Snegarova V, Lazova S, Velikova T
Vaccines (Basel). 2022; 10(12).
PMID: 36560485
PMC: 9781431.
DOI: 10.3390/vaccines10122075.
SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review.
Batsiou A, Mantzios P, Piovani D, Tsantes A, Kopanou Taliaka P, Liakou P
J Clin Med. 2022; 11(23).
PMID: 36498812
PMC: 9737360.
DOI: 10.3390/jcm11237238.
COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety.
Weaver K, Kappelman M, Long M
Gastroenterol Hepatol (N Y). 2022; 18(7):388-399.
PMID: 36397773
PMC: 9666812.
Humoral and cellular response to the COVID-19 vaccine in immunocompromised children.
Morgans H, Bradley T, Flebbe-Rehwaldt L, Selvarangan R, Bagherian A, Barnes A
Pediatr Res. 2022; 94(1):200-205.
PMID: 36376507
PMC: 9662120.
DOI: 10.1038/s41390-022-02374-4.
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens.
Cotugno N, Franzese E, Angelino G, Amodio D, Romeo E, Rea F
Vaccines (Basel). 2022; 10(7).
PMID: 35891273
PMC: 9318731.
DOI: 10.3390/vaccines10071109.
Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
Otten A, Bourgonje A, Horinga P, van der Meulen H, Festen E, van Dullemen H
Front Immunol. 2022; 13:920333.
PMID: 35865529
PMC: 9294156.
DOI: 10.3389/fimmu.2022.920333.
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis.
Sadeghi S, Kalantari Y, Shokri S, Fallahpour M, Nafissi N, Goodarzi A
J Clin Virol. 2022; 153:105196.
PMID: 35716417
PMC: 9162782.
DOI: 10.1016/j.jcv.2022.105196.
Predictors of seroconversion after coronavirus disease 2019 vaccination.
Chiarella S, Jenkins S, Smith C, Prasad V, Shakuntulla F, Ahluwalia V
Ann Allergy Asthma Immunol. 2022; 129(2):189-193.
PMID: 35640775
PMC: 9144839.
DOI: 10.1016/j.anai.2022.05.026.
Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
Vollenberg R, Tepasse P, Lorentzen E, Nowacki T
J Pers Med. 2022; 12(5).
PMID: 35629116
PMC: 9146879.
DOI: 10.3390/jpm12050694.
Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.
James D, Jena A, Bharath P, Choudhury A, Singh A, Sebastian S
Dig Liver Dis. 2022; 54(6):713-721.
PMID: 35382972
PMC: 8938236.
DOI: 10.1016/j.dld.2022.03.005.
Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression.
Bhurwal A, Mutneja H, Bansal V, Goel A, Arora S, Attar B
Aliment Pharmacol Ther. 2022; 55(10):1244-1264.
PMID: 35355306
PMC: 9111455.
DOI: 10.1111/apt.16913.
Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
Jena A, James D, Singh A, Dutta U, Sebastian S, Sharma V
Clin Gastroenterol Hepatol. 2022; 20(7):1456-1479.e18.
PMID: 35189387
PMC: 8856753.
DOI: 10.1016/j.cgh.2022.02.030.
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.
Vollenberg R, Tepasse P, Kuhn J, Hennies M, Strauss M, Rennebaum F
Biomedicines. 2022; 10(1).
PMID: 35052849
PMC: 8774019.
DOI: 10.3390/biomedicines10010171.
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S, Luong Nguyen L, Tartour E, de Lamballerie X, Wittkop L, Loubet P
Clin Microbiol Infect. 2022; 28(2):163-177.
PMID: 35020589
PMC: 8595936.
DOI: 10.1016/j.cmi.2021.09.036.
Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?.
Tepasse P, Vollenberg R, Nowacki T
Life (Basel). 2021; 11(11).
PMID: 34833096
PMC: 8620225.
DOI: 10.3390/life11111220.
